Earlier this week, The Washington Post falsely claimed that the PhRMA supported the Ensuring Patient Access and Effective Drug Enforcement Act of 2016 and spent $40 million advocating for its enactment. As stated previously, these claims are unequivocally false and last night The Washington Post issued a correction clarifying that PhRMA did not take a position on the legislation.
Recently, PhRMA has taken a number of steps to address the opioid crisis, such as announcing its support for a 7-day script limit on opioids for acute pain and launching a new partnership with the National Institutes of Health (NIH) and the National Institute on Drug Abuse (NIDA) to bring new non-opioid therapies to market for patients who need them.
We will continue to work with other stakeholders to fight this terrible epidemic.